 |
|
|
 |
Recombinant Human Keratinocyte Growth Factor (rHuKGF) Can Effectively Reduce Duration Of Severe Mucositis For People Undergoing Certain Cancer Therapies
New research findings demonstrate that recombinant human keratinocyte growth factor (rHuKGF) can effectively reduce the duration of severe mucositis-inflammation of mucous membranes in the mouth and throat -- for people undergoing certain cancer therapies. The results were reported today by Ricardo Spielberger, MD, Division of Hematology/Bone Marrow Transplantation (BMT), City of Hope Cancer Center, at the annual meeting of the American Society of Clinical Oncology in San Francisco. more
|
|
Brain Tumors Respond To Thalidomide And Radiation Therapy
The drug thalidomide, blamed for birth defects 40 years ago, now shows promise in treating malignant brain tumors in combination with radiation therapy, a Radiation Therapy Oncology Group (RTOG) study shows. The findings are to be presented during the American Society of Clinical Oncology (ASCO) annual meeting in San Francisco on 13 May 2001. more
|
|
|
|
Vioxx Vs. Celebrex: Which Is Better For Patients?
Findings from a six-week, replicate study of COX-2 specific inhibitors in treated, hypertensive osteoarthritis (OA) patients over 65 years of age have confirmed that more patients taking Vioxx experienced statistically significant and clinically important increases in systolic blood pressure (SBP) and edema versus patients taking Celebrex. The findings were presented today at the annual meeting of the American Geriatric Society (AGS) meeting. more
|
|
Prescribing Information: Celebrex (Celecoxib)
Celebrex (pronounced sell'-uh-brex) is for relief of the pain and inflammation of osteoarthritis and and adult rheumatoid arthritis and was introduced in the United States in early 1999. Since then, Celebrex has become the #1 selling brand of prescription arthritis medication. more
|
|
Docetaxel And Platinum Combination Superior To Standard First-Line Regimen For Lung Cancer
A chemotherapy regimen of docetaxel (Taxotere(R)) with cisplatin yields a significantly better overall survival rate (p=0.0469) than the combination of vinorelbine (Navelbine(R)) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) who have not undergone prior chemotherapy according to phase III trial data reported at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO). more
|
|
|
